ECSP045140A - Formulaciones farmacéuticas derivadas del platino - Google Patents

Formulaciones farmacéuticas derivadas del platino

Info

Publication number
ECSP045140A
ECSP045140A EC2004005140A ECSP045140A ECSP045140A EC SP045140 A ECSP045140 A EC SP045140A EC 2004005140 A EC2004005140 A EC 2004005140A EC SP045140 A ECSP045140 A EC SP045140A EC SP045140 A ECSP045140 A EC SP045140A
Authority
EC
Ecuador
Prior art keywords
platinum
pharmaceutical formulations
formulations derived
derived
formulas
Prior art date
Application number
EC2004005140A
Other languages
English (en)
Inventor
Sara Lauria
Alessandro Martini
Cristina Ciocca
Original Assignee
Pharmacia Italia Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21744006&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP045140(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa
Publication of ECSP045140A publication Critical patent/ECSP045140A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a nuevas fórmulas estables de oxaliplatino, en las cuales el ácido láctico y/o una sal farmacéuticamente aceptable funciona como un medio novedoso para preparar una unidad de dosis con una estabilidad mejorada. También está dentro del alcance de esta invención un método para elaborar tales formulaciones listas para ser administradas y su uso en una terapia contra tumores.
EC2004005140A 2001-12-06 2004-06-04 Formulaciones farmacéuticas derivadas del platino ECSP045140A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10/010,122 US6476068B1 (en) 2001-12-06 2001-12-06 Platinum derivative pharmaceutical formulations

Publications (1)

Publication Number Publication Date
ECSP045140A true ECSP045140A (es) 2004-08-27

Family

ID=21744006

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005140A ECSP045140A (es) 2001-12-06 2004-06-04 Formulaciones farmacéuticas derivadas del platino

Country Status (41)

Country Link
US (3) US6476068B1 (es)
EP (1) EP1453517B1 (es)
JP (1) JP2005515202A (es)
KR (1) KR100941210B1 (es)
CN (1) CN100540006C (es)
AP (1) AP1760A (es)
AR (1) AR037629A1 (es)
AT (1) ATE317260T1 (es)
AU (1) AU2002352105B2 (es)
BR (1) BR0214757A (es)
CA (1) CA2468916C (es)
CO (1) CO5580776A2 (es)
CR (1) CR7362A (es)
CY (1) CY1105608T1 (es)
DE (1) DE60209145T2 (es)
DK (1) DK1453517T3 (es)
EA (1) EA008090B1 (es)
EC (1) ECSP045140A (es)
ES (1) ES2258661T3 (es)
GE (1) GEP20063895B (es)
HR (1) HRP20040514A2 (es)
HU (1) HUP0402217A3 (es)
IL (2) IL162348A0 (es)
IS (1) IS2580B (es)
MA (1) MA27153A1 (es)
ME (1) MEP10408A (es)
MX (1) MXPA04005423A (es)
MY (1) MY134422A (es)
NO (1) NO330159B1 (es)
NZ (1) NZ533383A (es)
OA (1) OA12739A (es)
PL (1) PL206755B1 (es)
PT (1) PT1453517E (es)
RO (1) RO121509B1 (es)
RS (1) RS50360B (es)
SI (1) SI21493A (es)
TN (1) TNSN04104A1 (es)
TW (1) TW200409640A (es)
UA (1) UA77728C2 (es)
WO (1) WO2003047587A1 (es)
ZA (1) ZA200404525B (es)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1404689A1 (en) * 2001-07-02 2004-04-07 Debiopharm S.A. Oxaliplatin active substance with a very low content of oxalic acid
CA2388352A1 (en) * 2002-05-31 2003-11-30 Voiceage Corporation A method and device for frequency-selective pitch enhancement of synthesized speed
US20040022842A1 (en) * 2002-06-03 2004-02-05 Mebiopharm Co., Ltd. Liposome preparations containing oxaliplatin
DE10314377A1 (de) * 2003-03-28 2004-10-07 Stada Arzneimittel Ag Gebrauchsfertige Oxaliplatin-Lösungen
CN102048723A (zh) * 2003-08-28 2011-05-11 梅恩医药有限公司 含有酸的奥沙利铂制剂
GB2441445B (en) * 2003-08-28 2008-04-23 Mayne Pharma Ltd Acid containing oxaliplatin formulation
TWI347940B (en) * 2003-11-07 2011-09-01 Novartis Ag Methods for synthesizing quinolinone compounds
RU2273475C2 (ru) * 2004-04-06 2006-04-10 Государственное учреждение системы высшего и послевузовского профессионального образования "Сибирский государственный медицинский университет" (ГУ СВ ПО СибГМУ) Способ лечения диссеминированного колоректального рака
US7795205B2 (en) * 2004-04-12 2010-09-14 Canyon Pharmaceuticals, Inc. Methods for effecting regression of tumor mass and size in a metastasized pancreatic tumor
WO2005120480A1 (ja) * 2004-06-09 2005-12-22 Taiho Pharmaceutical Co., Ltd. 抗腫瘍効果増強剤、抗腫瘍剤及び癌治療方法
EP1658300A1 (en) * 2004-07-12 2006-05-24 Sicor Inc. Cis-diiodo- (trans-l-1,2-cyclohexanediamine) platinum (ii) complex and processes for preparing high purity oxaliplatin
US20060063833A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Ready-to-use oxaliplatin solutions
US20060063720A1 (en) * 2004-09-22 2006-03-23 Edgar Schridde Oxaliplatin solution concentrate
DE102004052877B4 (de) * 2004-11-02 2008-06-19 Ebewe Pharma Ges.M.B.H. Nfg.Kg Stabile wässrige Formulierungen eines Platin-Derivats
CN1311818C (zh) * 2004-11-22 2007-04-25 山东蓝金生物工程有限公司 一种抗实体肿瘤的药物组合物
DE102004063764A1 (de) * 2004-12-29 2006-07-13 Hexal Ag Kunststoff-Flasche für Oxaliplatin
JP2006248978A (ja) 2005-03-10 2006-09-21 Mebiopharm Co Ltd 新規なリポソーム製剤
AU2005329764B2 (en) * 2005-03-28 2010-08-12 Dabur Pharma Ltd. Stable pharmaceutical compositions of platinum (II) antitumour agents
WO2006124413A2 (en) * 2005-05-13 2006-11-23 Novartis Ag Methods for treating drug resistant cancer
DE102005038347A1 (de) * 2005-08-11 2007-02-15 Hexal Ag Herstellung einer Oxaliplatin-Lösung und Behälter sowie Behälter-Set mit der Lösung
WO2007029268A2 (en) * 2005-09-05 2007-03-15 Dabur Pharma Limited Stable oxaliplatin formulation
BRPI0619370A2 (pt) * 2005-11-29 2011-09-27 Novartis Ag formulações de quinolinonas
US20090076139A1 (en) * 2007-09-19 2009-03-19 Protia, Llc Deuterium-enriched oxalplatin
EP2152239A1 (en) 2007-11-12 2010-02-17 Intas Pharmaceuticals Limited Stable oxaliplatin composition for parenteral administration
EP2259776A4 (en) * 2008-02-29 2011-03-16 Eagle Pharmaceuticals Inc USEFUL TOPOTECAN SOLUTIONS
TW201021855A (en) * 2008-11-13 2010-06-16 Taigen Biotechnology Co Ltd Lyophilization formulation
EP2481396A4 (en) 2009-09-21 2014-03-05 Jw Pharmaceutical Corp OXALIPLATIN NANOPARTICLES AND MANUFACTURING METHOD THEREFOR
WO2012006101A2 (en) 2010-06-28 2012-01-12 The General Hospital Corporation Blood substitutes and uses thereof
CN102274171A (zh) * 2011-08-04 2011-12-14 上海希迪制药有限公司 一种奥沙利铂注射剂
JP2015524411A (ja) 2012-07-18 2015-08-24 オニキス セラピューティクス， インク．Ｏｎｙｘ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． エポキシケトン系プロテアソーム阻害剤のリポソーム組成物
JP5929607B2 (ja) * 2012-08-06 2016-06-08 ニプロ株式会社 オキサリプラチン製剤
CN102885765B (zh) * 2012-10-25 2013-11-06 哈药集团生物工程有限公司 一种盐酸伊立替康注射液及其制备方法
US10098813B2 (en) * 2014-09-03 2018-10-16 Sun Pharmaceutical Industries Limited Perfusion dosage form
KR101683635B1 (ko) 2014-12-29 2016-12-09 가천대학교 산학협력단 락테이트 금속염을 포함하는 암 치료용 약학 조성물
DK3256133T3 (da) * 2015-02-13 2022-10-24 Sun Pharmaceutical Ind Ltd Intravenøs infusionsdoseringsform
KR102293907B1 (ko) 2015-06-30 2021-08-26 한미약품 주식회사 이리노테칸 함유 경구용 고형제제 및 그 제조방법
ES2968415T3 (es) 2016-02-09 2024-05-09 Sun Pharmaceutical Ind Ltd Sistema de perfusión
EP3538546B1 (en) 2016-11-14 2025-01-08 Novartis AG Compositions, methods, and therapeutic uses related to fusogenic protein minion
CN111587110A (zh) 2018-01-12 2020-08-25 麦提麦迪制药有限公司 治疗慢性炎症性疾病的方法
KR101998246B1 (ko) 2018-08-22 2019-07-10 주식회사 메타파인즈 금속이온에 결합된 이온화합물을 포함하는 암 치료용 약학 조성물

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6041077B2 (ja) 1976-09-06 1985-09-13 喜徳 喜谷 １，２‐ジアミノシクロヘキサン異性体のシス白金（２）錯体
US5041578A (en) * 1988-11-22 1991-08-20 Board Of Regents, The University Of Texas System Water soluble 1,2-diaminocyclohexane platinum (IV) complexes as antitumor agents
WO1993009782A1 (en) 1991-11-15 1993-05-27 Smithkline Beecham Corporation Combination chemotherapy
JPH0776230B2 (ja) 1992-01-13 1995-08-16 田中貴金属工業株式会社 白金化合物の製造方法
JP2673331B2 (ja) 1993-01-12 1997-11-05 田中貴金属工業 株式会社 光学的に高純度なシス―オキザラート（トランス―１―１，２―シクロヘキサンジアミン）白金（▲ｉｉ▼）
JPH06287021A (ja) 1992-04-22 1994-10-11 Tanaka Kikinzoku Kogyo Kk 光学活性な白金錯化合物の光学的分割方法
WO1994012193A1 (fr) 1992-11-24 1994-06-09 Debiopharm S.A. Combinaison de cisplatine avec l'oxaliplatine
ES2224200T3 (es) * 1992-11-27 2005-03-01 Mayne Pharma (Usa) Inc. Composicion inyectable estable de paclitaxel.
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
US5455270A (en) * 1993-08-11 1995-10-03 Bristol-Myers Squibb Co. Stabilized solutions of platinum(II) antitumor agents
JP3547755B2 (ja) 1994-08-08 2004-07-28 デビオファーム・エス・アー オキサリプラティヌムの医薬的に安定な製剤
EP0715854B1 (en) 1994-11-11 2003-09-10 Debiopharm S.A. Carcinostatic compositions containing cis-oxaliplatinum and one or more other compatible carcinostatic substances
US5919816A (en) 1994-11-14 1999-07-06 Bionumerik Pharmaceuticals, Inc. Formulations and methods of reducing toxicity of antineoplastic agents
WO1996026949A1 (en) * 1995-02-28 1996-09-06 Debiopharm Sa Novel platinum (iv) complexes, process for producing the same, and carcinostatic agents containing the same
US5776959A (en) 1995-06-05 1998-07-07 Washington University Anticonvulsant and anxiolytic lactam and thiolactam derivatives
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
WO1997033894A1 (fr) * 1996-03-11 1997-09-18 Debiopharm Sa Complexes de platine dinucleaires, procede pour leur preparation et compositions pharmaceutiques en contenant
DE69725747T2 (de) 1996-08-23 2004-07-29 Sequus Pharmaceuticals, Inc., Menlo Park Liposome enthaltend cisplatin
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
IL131008A (en) 1997-02-05 2003-06-24 Upjohn Co Lipid complexes and liposomes of highly insoluble platinum complex dicarboxylate
AU6178198A (en) 1997-03-07 1998-09-22 Sanofi Pharmaceuticals, Inc. Method of treating a tumor
GB9727523D0 (en) 1997-12-31 1998-02-25 Pharmacia & Upjohn Spa Alpha-aminoamide derivatives useful as analgesic agents
GB9804013D0 (en) * 1998-02-25 1998-04-22 Sanofi Sa Formulations
US6866857B1 (en) 1998-10-14 2005-03-15 Debiopharm S.A. Oxalipatinum preparation packaging
CA2382389C (fr) 1999-08-30 2010-06-29 Debiopharm S.A. Preparation pharmaceutique stable d'oxaliplatine pour administration par voie parenterale
AU2001240001A1 (en) 2000-03-08 2001-09-17 Bristol-Myers Squibb Company Oral dosage form for administration of the combination of tegafur, uracil, folinic acid, and oxaliplatin and method of using the same
SE0003026D0 (sv) * 2000-08-25 2000-08-25 Kerstin Sunnerheim Use for conifer sapling protection

Also Published As

Publication number Publication date
AP2004003055A0 (en) 2004-06-30
CY1105608T1 (el) 2010-12-22
US20030109515A1 (en) 2003-06-12
IL162348A0 (en) 2005-11-20
CR7362A (es) 2009-02-12
US6476068B1 (en) 2002-11-05
IS7298A (is) 2004-06-03
CN100540006C (zh) 2009-09-16
BR0214757A (pt) 2004-09-14
GEP20063895B (en) 2006-08-10
DK1453517T3 (da) 2006-06-19
KR100941210B1 (ko) 2010-02-10
MA27153A1 (fr) 2005-01-03
YU59704A (sh) 2006-08-17
UA77728C2 (en) 2007-01-15
AU2002352105A1 (en) 2003-06-17
DE60209145D1 (de) 2006-04-20
WO2003047587A1 (en) 2003-06-12
RO121509B1 (ro) 2007-10-30
SI21493A (sl) 2004-12-31
NO330159B1 (no) 2011-02-28
HRP20040514A2 (en) 2004-10-31
EA200400777A1 (ru) 2004-12-30
EP1453517B1 (en) 2006-02-08
HUP0402217A3 (en) 2005-11-28
EA008090B1 (ru) 2007-02-27
TNSN04104A1 (fr) 2006-06-01
MY134422A (en) 2007-12-31
AP1760A (en) 2007-07-18
US6673805B2 (en) 2004-01-06
TW200409640A (en) 2004-06-16
CA2468916A1 (en) 2003-06-12
MXPA04005423A (es) 2004-10-11
MEP10408A (en) 2011-02-10
NZ533383A (en) 2007-02-23
IL162348A (en) 2010-11-30
RS50360B (sr) 2009-11-10
CN1612737A (zh) 2005-05-04
OA12739A (en) 2006-06-30
HK1072002A1 (zh) 2005-08-12
KR20050058278A (ko) 2005-06-16
HUP0402217A2 (hu) 2005-01-28
PL370254A1 (en) 2005-05-16
CA2468916C (en) 2009-01-20
PT1453517E (pt) 2006-06-30
JP2005515202A (ja) 2005-05-26
ES2258661T3 (es) 2006-09-01
PL206755B1 (pl) 2010-09-30
ZA200404525B (en) 2005-08-15
AU2002352105B2 (en) 2009-12-03
IS2580B (is) 2010-02-15
EP1453517A1 (en) 2004-09-08
NO20042842L (no) 2004-07-05
US20030109514A1 (en) 2003-06-12
AR037629A1 (es) 2004-11-17
CO5580776A2 (es) 2005-11-30
ATE317260T1 (de) 2006-02-15
DE60209145T2 (de) 2006-10-26

Similar Documents

Publication Publication Date Title
AR037629A1 (es) Formulaciones farmaceuticas que comprenden un derivado de platino
CY1116464T1 (el) Θεραπεια συνδυασμου για τη θεραπευτικη αγωγη διαταραχων ανεπαρκειας πρωτεϊνης
SA520411119B1 (ar) تركيبات جسيم شحمي تشمل عقاقير مكونة من حمض ضعيف واستخداماتها
CY1112376T1 (el) Παραγωγα 2,3,4,9-τετραϋδρο-1η-καρβαζολης ως ανταγωνιστες του υποδοχεα crth2
NO20075136L (no) Nye liposompreparater
BG106095A (bg) Нови лекарствени състави на базата на антихолинергично активни съединения и бета-миметици
CY1111159T1 (el) Πυκνα διαλυματα μεθοτρεξατης
BRPI0416796A (pt) compostos orgánicos
BR0316050A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com terapia de radiação, terapia hormonal, terapia biológica, ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
BRPI0414867A (pt) pirazolopiridinas e seus análogos
BRPI0418157A (pt) terapêutica de tumores alogênicos
CU23208A3 (es) Oxazolidinonas sustituidas y su uso en el campo de la coagulacion sanguinea
CO6160321A2 (es) Uso de 2-6-(3-amino-piperidin-1-il)-3-metil-2,4-dioxo-3,4-dihidro-2h-pirimidin-1-ilmetil-4-fluoro-benzonitrilo
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
MX2020005518A (es) Mezclas no racemicas y usos de las mismas.
NO20024646L (no) Kombinasjonsterapier med vaskul¶r-skadende aktivitet
BR0316057A (pt) Métodos de tratar, controlar ou prevenir um câncer especìfico e uma doença associada com angiogênese indesejada e de reduzir ou evitar um efeito adverso associado com a administração de um segundo ingrediente ativo e com a terapia de radiação, terapia hormonal, terapia biológica ou imunoterapia em um paciente sofrendo de um câncer especìfico, composição farmacêutica e kit
EA200602092A1 (ru) Способ и композиция для лечения ринита
AR080096A1 (es) Tratamiento combinado de cancer de pancreas con gemcitabina y masitinib
Bowe et al. Therapeutic update: acne
BRPI0409380A (pt) composições farmacêuticas
SE0401655D0 (sv) New compounds
PT1343472E (pt) Pulverizacao nasal tixotropica
AR039895A1 (es) Composicion que comprende una vitamina, una sal de metal y una insulina o una hormona del crecimiento y uso de dichos componentes para prepararla
JP2004002429A5 (es)